×

Do you want to link to this External Site and leave Amgen.com?

YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

×

Do you want to link to this External Site and leave Amgen.com?

YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

×

Do you want to link to this External Site and leave Amgen.com?

YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

×

Do you want to link to this External Site and leave Amgen.com?

YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

Amgen Astellas BioPharma Appoints Leadership Team, Begins Operations

Amgen Astellas BioPharma K.K., a joint venture between Amgen and Astellas, a leading Tokyo-based, global pharmaceutical company, officially began business operations on October 1, 2013.

Amgen Astellas BioPharma is the product of a unique alliance between Amgen and Astellas that was announced in May of 2013 and focuses on the co-development and co-commercialization in Japan of five Amgen pipeline medicines.  The new joint venture company is headquartered in Tokyo and will be led by Eiichi Takahashi, who serves as general manager.

To learn more, visit www.aabp.co.jp.

Amgen Astellas Biopharma Team

The Amgen Astellas BioPharma team celebrates the opening of the joint venture in Tokyo on October 1.